0001171843-18-001105.txt : 20180213 0001171843-18-001105.hdr.sgml : 20180213 20180213165248 ACCESSION NUMBER: 0001171843-18-001105 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180213 FILED AS OF DATE: 20180213 DATE AS OF CHANGE: 20180213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON JOHN CENTRAL INDEX KEY: 0001410781 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33609 FILM NUMBER: 18604349 MAIL ADDRESS: STREET 1: DENDREON CORPORATION STREET 2: 1301 2ND AVENUE CITY: SEATTLE STATE: WA ZIP: 98101 FORMER NAME: FORMER CONFORMED NAME: Johnson John H DATE OF NAME CHANGE: 20070827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sucampo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001365216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133929237 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 805 KING FARM BOULEVARD, SUITE 550 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 3019613400 MAIL ADDRESS: STREET 1: 805 KING FARM BOULEVARD, SUITE 550 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 form4.xml OWNERSHIP DOCUMENT X0306 4 2018-02-13 1 0001365216 Sucampo Pharmaceuticals, Inc. SCMP 0001410781 JOHNSON JOHN 805 KING FARM BLVD, SUITE 550 ROCKVILLE MD 20850 1 0 0 0 Common Stock, Class A 2018-02-13 4 D 0 5130 18.00 D 0 D Director Stock Option (right to buy) 13.92 2018-02-13 4 D 0 30000 4.08 D 2024-12-10 Common Stock 30000 0 D Director Stock Option (right to buy) 16.23 2018-02-13 4 D 0 20000 1.77 D 2025-05-29 Common Stock 20000 0 D Director Stock Option (right to buy) 10.30 2018-02-13 4 D 0 10000 7.70 D 2025-05-29 Common Stock 10000 0 D This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement. This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. /s/ John H. Johnson 2018-02-13